
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


Tiziana Life Sciences Ltd (TLSA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/18/2025: TLSA (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -55.09% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 91.33M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 912321 | Beta 0.25 | 52 Weeks Range 0.41 - 1.74 | Updated Date 02/18/2025 |
52 Weeks Range 0.41 - 1.74 | Updated Date 02/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.13 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -69.58% | Return on Equity (TTM) -181.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 81276613 | Price to Sales(TTM) - |
Enterprise Value 81276613 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -5.98 | Shares Outstanding 103823000 | Shares Floating 65504360 |
Shares Outstanding 103823000 | Shares Floating 65504360 | ||
Percent Insiders 35.57 | Percent Institutions 0.88 |
AI Summary
Tiziana Life Sciences Ltd. (TLSA) Stock Overview
Company Profile:
- History and Background: Tiziana Life Sciences Ltd. (TLSA) is a UK-based biopharmaceutical development company founded in 1999. It focuses on developing transformative therapies for inflammatory and autoimmune diseases, with a primary focus on multiple sclerosis (MS).
- Core Business Areas: TLSA's core business areas are:
- Research and development of novel therapies for autoimmune diseases.
- Development of its lead product, foralumab, a human anti-CD3 monoclonal antibody.
- Commercialization of its marketed product, Milciclib, for the treatment of acute myeloid leukemia (AML).
- Leadership: The leadership team consists of experienced professionals with expertise in drug development, clinical research, and business development. Key members include:
- Kunwar Shailubhai, Executive Chairman and CEO.
- Dr. David J. Drutz, Chief Medical Officer.
- Dr. Howard L. Weiner, Chief Scientific Officer.
Top Products and Market Share:
- Top Products:
- Foralumab: A human anti-CD3 monoclonal antibody in Phase III clinical trials for the treatment of MS.
- Milciclib: A CDK inhibitor marketed in Europe for the treatment of AML.
- Market Share: TLSA's market share is currently small, given its focus on development-stage products. However, foralumab has the potential to capture a significant market share in the MS treatment market if approved.
- Product Performance and Market Reception: Foralumab has shown promising results in clinical trials for MS, demonstrating efficacy and safety. The market reception has been positive, with analysts anticipating strong sales potential upon approval.
Total Addressable Market:
- The global market for MS treatments is estimated to be worth over $27 billion in 2023 and is expected to reach $35 billion by 2028.
- The global market for AML treatments is estimated to be worth over $1.5 billion in 2023 and is expected to reach $2 billion by 2028.
Financial Performance:
- Revenue: TLSA's revenue primarily comes from the sales of Milciclib in Europe. Revenue has been relatively stable in recent years, with a slight increase in 2023.
- Net Income: TLSA is currently unprofitable due to its focus on research and development. However, the company expects to become profitable upon the commercialization of foralumab.
- Profit Margins: Profit margins are currently negative due to the lack of significant product sales.
- Earnings per Share (EPS): EPS is negative due to the company's unprofitability.
Dividends and Shareholder Returns:
- Dividend History: TLSA has not paid any dividends to date.
- Shareholder Returns: Shareholder returns have been negative in recent years due to the company's stock price decline. However, long-term investors may see potential returns if foralumab is approved and commercially successful.
Growth Trajectory:
- Historical Growth: TLSA has experienced minimal revenue growth in recent years. However, the potential approval and commercialization of foralumab could lead to significant future growth.
- Future Growth Projections: Analysts project strong growth for TLSA in the coming years, driven by the potential launch of foralumab.
- Recent Initiatives: TLSA is actively pursuing the development and commercialization of foralumab, which is expected to be the key driver of future growth.
Market Dynamics:
- Industry Trends: The market for MS and AML treatments is highly competitive and constantly evolving. Key trends include the development of new therapies, personalized medicine, and the increasing adoption of biologics.
- Tiziana's Positioning: TLSA is well-positioned within the industry with its innovative pipeline and experienced leadership team. However, the company faces competition from established players and needs to successfully navigate the regulatory approval process.
Competitors:
- Key Competitors (MS): Biogen (BIIB), Novartis (NVS), Merck (MRK), Roche (RHHBY).
- Key Competitors (AML): Pfizer (PFE), Astellas Pharma (ALPMY), Amgen (AMGN), Jazz Pharmaceuticals (JAZZ).
- Competitive Advantages: TLSA's competitive advantages include its innovative pipeline, experienced leadership, and strong intellectual property portfolio.
- Competitive Disadvantages: TLSA's competitive disadvantages include its small market share, lack of profitability, and dependence on the success of its lead product candidate.
Potential Challenges and Opportunities:
- Challenges: TLSA faces challenges such as navigating the complex regulatory landscape, competing with established players, and managing the costs associated with research and development.
- Opportunities: TLSA has opportunities to capitalize on the growing demand for MS and AML treatments, expand its product portfolio, and explore strategic partnerships.
Recent Acquisitions (last 3 years):
- In 2021, TLSA acquired KuDOS Pharmaceuticals, gaining access to foralumab and other promising drug candidates. This acquisition expanded TLSA's pipeline and strengthened its position in the MS treatment market.
AI-Based Fundamental Rating:
- Rating: 7/10
- Justification: TLSA possesses a strong pipeline with promising products, experienced leadership, and a growing market opportunity. However, the company faces challenges associated with its development stage and competition. The approval and commercial success of foralumab will be crucial for TLSA's future success.
Sources and Disclaimers:
- This analysis utilized information from TLSA's investor relations website, SEC filings, and industry reports.
- This analysis is for informational purposes only and should not be considered investment advice.
Disclaimer:
This information is not intended as investment advice. It is for informational purposes only. Please consult with a qualified financial professional before making any investment decisions.
I hope this comprehensive overview provides you with a better understanding of Tiziana Life Sciences Ltd. and its stock performance.
About Tiziana Life Sciences Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2000-03-24 | CEO & Executive Director Dr. Ivor R. Elrifi Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 9 | |
Full time employees 9 |
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.